Randomized trial · people

NSI-189 80 mg beat placebo in moderate, not severe, depression

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, the antidepressant benefit of NSI-189 showed up in moderate rather than severe depression. Because it came from an after-the-fact split, it is a lead to test, not a settled result.

Kind
Randomized trial
Studied in
People
Number studied
220
Published
2020
Journal
Ann Clin Psychiatry

What they tested

Did the effect of NSI-189 on depression and thinking skills differ depending on how severe a person's depression was at the start?

How the study was done

A randomized, placebo-controlled phase 2 trial in 220 patients with major depressive disorder, who took NSI-189 40 mg, NSI-189 80 mg or placebo (a dummy pill) daily for 12 weeks, tested in two 6-week stages. This analysis was done after the trial ended (post hoc) and split patients by a starting score of 30 on the MADRS, a depression rating scale.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking NSI-189? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Splitting patients by how severe their depression was at the start made the effect of NSI-189 look larger. In patients with moderate depression (MADRS below 30), the 80 mg arm did significantly better than placebo on the MADRS-6 score. In patients with severe depression (MADRS of 30 or more), the difference was not significant. On CogScreen measures of thinking skills, 11/36 (31%) improved significantly in the moderate group, compared with 5/36 (14%) in the severe group and 7/36 (19%) across the whole study.

What it doesn’t show

This was a post hoc subgroup analysis, so the moderate-versus-severe split was not the trial's original test and needs checking in a new trial. The significant depression result came from one dose on one version of the scale, over 12 weeks.

The paper

Johe et al. NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder. Ann Clin Psychiatry. 2020.

The compound

More studies on NSI-189

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking NSI-189? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo